
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies is globally recognized as a leader in developing innovative treatments for pediatric and young adult osteosarcoma, with its lead drug OST-HER2 demonstrating promising immune activation and potential for accelerated approval. The company's coordinated regulatory engagement and planned Phase 3 trial further de-risk its regulatory path, while the potential for a Priority Review Voucher presents a significant non-dilutive financing opportunity. However, potential risks such as clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share must be considered in the investment case.
Bears say
OS Therapies is a clinical-stage biopharmaceutical company with an innovative pipeline of immunotherapy and tunable drug conjugate treatments for solid cancers. However, the company faces significant risks in terms of clinical and regulatory hurdles, potential partnership and financial risks, as well as legal and intellectual property risks. Despite promising Phase 2b data and upcoming meetings with regulatory agencies, the focus should remain on whether biomarker data will be accepted for an accelerated approval pathway, creating uncertainty for investors in the near term.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares